Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast: Subset Analysis of Patients With Scalp Psoriasis in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要